Gilead Prices Cystic Fibrosis Drug Cayston At Slight Premium To Competitor
Executive Summary
Gilead Sciences will price its cystic fibrosis drug Cayston at an 8 percent premium to its competitor, Novartis' TOBI (tobramycin)
You may also be interested in...
Cystic Fibrosis Trials: CDER Officials Disagree Over Value Of FEV1 Endpoint
There is an apparent split within FDA's Center for Drug Evaluation and Research on the usefulness of measuring the amount of air a patient can blow in one second as a primary outcome measure in trials of aerosolized antimicrobial drugs for cystic fibrosis.
Cystic Fibrosis Trials: CDER Officials Disagree Over Value Of FEV1 Endpoint
There is an apparent split within FDA's Center for Drug Evaluation and Research on the usefulness of measuring the amount of air a patient can blow in one second as a primary outcome measure in trials of aerosolized antimicrobial drugs for cystic fibrosis.
Non-Inferiority Studies May (Bio)Creep Out Of Limelight After GAO Report
A report on FDA's use of non-inferiority trials by the Government Accountability Office could in fact signal the end of the political wrangling over the study method